PALBOCICLIB + ENDOCRINE THERAPY FOR HR+ BrCa
Phase: Phase 2
Diagnosis: Breast: Metastatic, Breast: Early Stage Disease
NCT ID: NCT02040857
(View complete trial on ClinicalTrials.gov)
DFCI Protocol ID: 13-559
This research study is evaluating a drug called Palbociclib in combination with endocrine therapy as a possible treatment for hormone receptor positive breast cancer. - Palbociclib is a drug that may stop cancer cells from growing. Palbociclib blocks activity of two closely related enzymes (proteins that help chemical reactions in the body occur), called Cyclin D Kinases 4 and 6 (CDK 4/6). These proteins are part of a pathway, or a sequence of steps which is known to regulate cell growth. Laboratory testing has suggested palbociclib may stop the growth of hormone receptor positive breast cancer. - Endocrine therapy prevents breast cancer cell growth by blocking estrogen stimulation. During this study endocrine therapy will either be tamoxifen or an aromatase inhibitor. It is standard of care for premenopausal women to take tamoxifen and for postmenopausal women to take either an aromatase inhibitor or tamoxifen after a diagnosis of hormone receptor positive breast cancer.
Dana-Farber Cancer Institute, Brigham and Women's Hospital, Beth-Israel Deaconess Medical Center, Massachusetts General Hospital
Erica Mayer, MD,
Dana-Farber Cancer Institute
Steven Come, MD,
Beth Israel Deaconess Medical Center
Massachusetts General Hospital
Dana-Farber Cancer Institute:
Breast Cancer Nursing Team, 617-632-3478
Beth-Israel Deaconess Medical Center:
Cancer Trials Call Center, 617-667-3060
Massachusetts General Hospital:
Cancer Trials Call Center, 877-789-6100
- Participants must have histologically confirmed hormone receptor positive (HR+) HER2
negative stage II (except T2N0) or stage III invasive breast cancer. Evaluation for
metastatic disease is not required in the absence of symptoms.
- Postmenopausal women only are eligible.
- Prior Treatment:
- Participants may have received (neo)adjuvant chemotherapy, but must be at least
30 days after last dose, with no more than grade 1 residual toxicity at time of
- Participants may have received adjuvant radiotherapy, but must be at least 30
days after last dose , with no more than grade 1 residual toxicity at the time
- If most recent therapy was surgery, participants must be at least 30 days out
from definitive surgery with no active wound healing complications.
- Participants must have demonstrated ability to tolerate aromatase inhibitor (AI)
therapy by prior successful completion of at least 3 months of AI therapy without
significant adverse events, and in the opinion of the treating physician any ongoing
toxicity does not preclude ability to continue on AI for at least a projected 2 year
continuous duration. Ongoing use of any AI, including letrozole, anastrozole, or
exemestane, is allowed. Patients may enroll within 2 years of beginning AI therapy,
as long as there is a plan for at least 2 more years of adjuvant AI therapy.
- ECOG performance status 0-1
- Age ≥18 years.
- Normal organ and marrow function
- Baseline QTc ≤ 480 ms
- The effects of palbociclib on the developing human fetus are unknown. Women who might
become pregnant must use adequate contraception
- Ability to understand and the willingness to sign a written informed consent document
- Concurrent therapy with other investigational agents.
- Prior therapy with any CDK4/6 inhibitor.
- History of allergic reactions attributed to compounds of similar chemical or biologic
composition to palbociclib.
- Participants receiving any medications or substances that are strong inhibitors or
inducers of CYP3A isoenzymes are ineligible.
- Current use of drugs that are known to prolong the QT interval
- Subjects with organ allograft requiring immunosuppression.
- Uncontrolled intercurrent illness including, but not limited to ongoing or active
infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac
arrhythmia, or psychiatric illness/social situations that would limit compliance with
- Pregnant women are excluded from this study. Breastfeeding should be discontinued
prior to entry onto the study.
- Individuals with a history of a different malignancy are ineligible except for the
following circumstances. Individuals with a history of other malignancies are
eligible if they have been disease-free for at least 5 years and are deemed by the
investigator to be at low risk for recurrence of that malignancy. Individuals with
the following cancers are eligible if diagnosed and treated within the past 5 years:
ductal carcinoma in situ of the breast, cervical cancer in situ, and basal cell or
squamous cell carcinoma of the skin.
- No ongoing combination antiretroviral therapy